Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Declines By 17.5%

PolyPid Ltd. (NASDAQ:PYPD) saw a large decrease in short interest during the month of March. As of March 31st, there was short interest totalling 3,300 shares, a decrease of 17.5% from the March 15th total of 4,000 shares. Based on an average daily volume of 4,500 shares, the short-interest ratio is presently 0.7 days. Approximately 0.4% of the company’s shares are short sold.

PolyPid Stock Up 2.2 %

Shares of NASDAQ:PYPD opened at $4.60 on Monday. PolyPid has a 12 month low of $3.57 and a 12 month high of $14.10. The firm’s 50-day moving average is $5.42 and its 200 day moving average is $4.98. The company has a current ratio of 0.83, a quick ratio of 0.83 and a debt-to-equity ratio of 2.17.

PolyPid (NASDAQ:PYPD) last issued its quarterly earnings results on Wednesday, February 14th. The company reported ($3.97) EPS for the quarter, missing the consensus estimate of ($2.17) by ($1.80). As a group, sell-side analysts expect that PolyPid will post -3.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On PolyPid

Hedge funds have recently added to or reduced their stakes in the stock. UBS Group AG grew its stake in PolyPid by 29.9% in the 1st quarter. UBS Group AG now owns 285,399 shares of the company’s stock worth $1,558,000 after acquiring an additional 65,746 shares in the last quarter. Silverarc Capital Management LLC grew its stake in PolyPid by 1.2% in the 1st quarter. Silverarc Capital Management LLC now owns 218,175 shares of the company’s stock worth $1,191,000 after acquiring an additional 2,555 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its stake in PolyPid by 83.3% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 52,251 shares of the company’s stock worth $285,000 after acquiring an additional 23,752 shares in the last quarter. Renaissance Technologies LLC bought a new position in PolyPid in the 1st quarter worth about $72,000. Finally, Boothbay Fund Management LLC grew its stake in PolyPid by 514.5% in the 1st quarter. Boothbay Fund Management LLC now owns 122,898 shares of the company’s stock worth $57,000 after acquiring an additional 102,898 shares in the last quarter. 26.47% of the stock is currently owned by institutional investors.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage pharmaceutical company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which helps in the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs.